Patents by Inventor John T. Belisle
John T. Belisle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220170066Abstract: The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.Type: ApplicationFiled: November 23, 2021Publication date: June 2, 2022Applicants: Colorado State University Research Foundation, The United States of America, as represented by the secretary, Department of Health and Human ServicInventors: John T. Belisle, Claudia R. Molins, Gary P. Wormser
-
Patent number: 11230728Abstract: The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.Type: GrantFiled: December 4, 2019Date of Patent: January 25, 2022Assignees: Colorado State University Research Foundation, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John T. Belisle, Claudia R. Molins, Gary P. Wormser
-
Patent number: 10669567Abstract: The present disclosure provides methods for detecting early Lyme disease. The present disclosure provides a biosignature indicative of the presence or absence of Borrelia burgdorferi infection.Type: GrantFiled: February 17, 2016Date of Patent: June 2, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Colorado State University Research Foundation, New York Medical CollegeInventors: John T. Belisle, Claudia R. Molins, Gary P. Wormser
-
Publication number: 20200140915Abstract: The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.Type: ApplicationFiled: December 4, 2019Publication date: May 7, 2020Applicants: Colorado State University Research Foundation, The United States of America, as represented by the secretary, Department of Health and Human ServicInventors: John T. Belisle, Claudia R. Molins, Gary P. Wormser
-
Publication number: 20160237470Abstract: The present disclosure provides methods for detecting early Lyme disease. The present disclosure provides a biosignature indicative of the presence or absence of Borrelia burgdorferi infection.Type: ApplicationFiled: February 17, 2016Publication date: August 18, 2016Inventors: John T. Belisle, Claudia R. Mollins, Gary P. Wormser
-
Patent number: 8580490Abstract: A method for metabolomically evaluating a subject's response to an anti-mycobacterial agent. The method includes the steps of generating multiple small molecule profiles using samples collected from the subject at or immediately prior to the start of treatment and at a times subsequent to the start of treatment with the anti-mycobacterial agent, identifying predetermined biomarkers in the small molecule profiles of the subject and comparing to a known standard established for the agent as an indication of whether the human is benefiting from treatment with the agent. Also provided are methods of monitoring treatment compliance, methods for establishing biomarkers indicative of treatment efficacy and validated biomarkers shown to be effective in assessing efficacy of anti-tuberculosis drugs.Type: GrantFiled: June 6, 2011Date of Patent: November 12, 2013Assignee: Colorado State University Research FoundationInventors: John T. Belisle, Sebabrata Mahapatra
-
Publication number: 20110111017Abstract: The invention provides compositions featuring cationic liposome nucleic acid molecules complexed with pathogen derived antigen and methods of using such compositions for the treatment or prevention of an infectious disease. Other features and advantages of the invention will be apparent from the detailed description, and from the claims.Type: ApplicationFiled: February 24, 2009Publication date: May 12, 2011Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA,AS REP. BY THE SECRETARY,DEPT. OF HEALTH AND HUMAN SERVICInventors: Catharine M. Bosio, John T. Belisle, Jeffrey Fairman
-
Patent number: 7807182Abstract: A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an 88 kDa secreted protein, GlcB (SEQ ID NO:106) and of Mtb antigen MPT51 (SEQ ID NO:107) have been identified. These peptides, variants thereof, peptide multimers thereof that include two or more repeats of one or more of the peptides, and fusion polypeptides that include early Mtb antigenic proteins, peptides or both, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mtb antibodies. The antigenic proteins and peptides are also used in vaccine compositions.Type: GrantFiled: August 2, 2002Date of Patent: October 5, 2010Assignees: Colorado State University Research Foundation, New York UniversityInventors: Suman Laal, Susan Zolla-Pazner, John T. Belisle
-
Patent number: 7776341Abstract: Mycobacterial proteins from culture filtrate or cytosol are disclosed as being useful B cell antigens for early diagnosis of mycobacterial disease, particularly in humans. These proteins include four that had not previously been recognized as B cell antigens (LppZ protein encoded by Mtb gene Rv3006; SodC protein encoded by Mtb gene Rv0432; BfrB protein encoded by Mtb gene Rv3841 and TrxC protein encoded by Mtb gene Rv3914). Antigenic compositions include these proteins and/or peptide fragments thereof, in various combinations with each other or with one or more of a set of 10 additional Mtb proteins known to be antigens (in particular early antigens. Methods and kits for using these antigenic composition for early diagnosis of mycobacterial infection and disease are also disclosed.Type: GrantFiled: August 10, 2007Date of Patent: August 17, 2010Assignees: Colorado State University Research Foundation, New York UniversityInventors: John T. Belisle, Mark J. Sartain, Suman Laal
-
Publication number: 20090280140Abstract: A number of protein and glycoprotein antigens secreted by Mycobacterium tuberculosis (Mtb) have been identified as “early” Mtb antigens on the basis early antibodies present in subjects infected with Mtb prior to the development of detectable clinical disease. Epitope-bearing peptide fragments of these early Mtb antigens, in particular of an 88 kDa secreted protein, GlcB (SEQ ID NO:106) and of Mtb antigen MPT51 (SEQ ID NO:107) have been identified. These peptides, variants thereof, peptide multimers thereof that include two or more repeats of one or more of the peptides, and fusion polypeptides that include early Mtb antigenic proteins, peptides or both, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mtb antibodies. The antigenic proteins and peptides are also used in vaccine compositions.Type: ApplicationFiled: August 2, 2002Publication date: November 12, 2009Inventors: Suman Laal, Susan Zolla-Pazner, John T. Belisle
-
Publication number: 20080171345Abstract: Mycobacterial proteins from culture filtrate or cytosol are disclosed as being useful B cell antigens for early diagnosis of mycobacterial disease, particularly in humans. These proteins include four that had not previously been recognized as B cell antigens (LppZ protein encoded by Mtb gene Rv3006; SodC protein encoded by Mtb gene Rv0432; BfrB protein encoded by Mtb gene Rv3841 and TrxC protein encoded byMtb gene Rv3914). Antigenic compositions include these proteins and/or peptide fragments thereof, in various combinations with each other or with one or more of a set of 10 additional Mtb proteins known to be antigens (in paricular early antigens. Methods and kits for using these antigenic composition for early diagnosis of mycobacterial infection and disease are also disclosed.Type: ApplicationFiled: August 10, 2007Publication date: July 17, 2008Applicants: Colorado State University Research Foundation, New York UniversityInventors: John T. BELISLE, Mark J. Sartain, Suman Laal
-
Patent number: 7288261Abstract: Vaccine compositions for boosting immunity to mycobacteria when administered in mid-life in a subject who has been vaccinated neonatally or in early childhood with BCG and in whom protective immunity has waned comprise one or more purified immunogenic proteins from Mycobacterium tuberculosis from a group of 30 proteins that stimulate T cell immunity and interferon-? secretion. A preferred protein is Ag85A, the secreted product (SEQ ID NO:31) of the Rv3084c gene. Also disclosed are methods for boosting immunity in such BCG-vaccinated subjects comprising administering an effective amount of the above vaccine composition.Type: GrantFiled: July 10, 2001Date of Patent: October 30, 2007Assignee: Colorado State University Research FoundationInventors: Ian M. Orme, John T. Belisle
-
Publication number: 20040180056Abstract: Vaccine compositions for boosting immunity to mycobacteria when administered in mid-life in a subject who has been vaccinated neonatally or in early childhood with BCG and in whom protective immunity has waned comprise one or more purified immunogenic proteins from Mycobacterium tuberculosis from a group of 30 proteins that stimulate T cell immunity and interferon-&ggr; secretion. A preferred protein is Ag85A, the secreted product (SEQ ID NO:31) of the Rv3084c gene. Also disclosed are methods for boosting immunity in such BCG-vaccinated subjects comprising administering an effective amount of the above vaccine composition.Type: ApplicationFiled: November 24, 2003Publication date: September 16, 2004Inventors: Ian M Orme, John T Belisle
-
Patent number: 6506384Abstract: A number of protein and glycoprotein antigens secreted by Mycobacterium. tuberculosis (Mt) have been identified as “early” Mt antigens on the basis early antibodies present in subjects infected with Mt prior to the development of detectable clinical disease. These early Mt antigens, in particular an 88 kDa secreted protein having a pI of about 5.2 and the sequence of SEQ ID NO:106, which is present in Mt lipoarabinomannan-free culture filtrate, a protein characterized as Mt antigen 85C; a protein characterized as Mt antigen MPT51, a glycoprotein characterized as Mt antigen MPT32; and a 49 kDa protein having a pI of about 5.1, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mt antigen, an early Mt antibody, and immune complexes thereof.Type: GrantFiled: September 14, 1999Date of Patent: January 14, 2003Assignees: New York University, Colorado State University Research FoundationInventors: Suman Laal, Susan Zolla-Pazner, John T. Belisle
-
Patent number: 6245331Abstract: A number of protein and glycoprotein antigens secreted by Mycobacterium. tuberculosis (Mt) have been identified as “early” Mt antigens on the basis early antibodies present in subjects infected with Mt prior to the development of detectable clinical disease. These early Mt antigens, in particular an 88 kDa secreted protein having a pI of about 5.2 present in Mt lipoarabinomannan-free culture filtrate, a protein characterized as Mt antigen 85C; a protein characterized as Mt antigen MPT51, a glycoprotein characterized as Mt antigen MPT32; and a 49 kDa protein having a pI of about 5.1, are useful in immunoassay methods for early, rapid detection of TB in a subject. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mt antigen, an early Mt antibody, and immune complexes thereof.Type: GrantFiled: December 31, 1997Date of Patent: June 12, 2001Assignees: New York Univ. Medical Center, Colorado State UniversityInventors: Suman Laal, Susan Zolla-Pazner, John T. Belisle